摘要
目的探讨乙型肝炎病毒肿瘤标志物与肝癌的发病关系。方法研究120例乙肝病毒携带者。60例用红花清肝十三味丸治疗,30例用护肝胶囊治疗,30例不用任何药物治疗,观察三组肿瘤标志物的变化,并进行5年后的长期随访。FQ-PCR方法检测血清HBV-DNA含量。另外实验室用四氯化碳造成肝损伤模型,观察红花清肝十三味丸的保肝作用。结果①护肝胶囊组和红花清肝组对AFP、AFU、r-QT、CEA四种肿瘤标志物浓度的降低明显优于非用药组。②长期随访(5年后)对乙肝病毒标志物(HBV-DNA)的降低护肝胶囊组和红花清肝十三味丸组明显优于非用药组。③长期随访(5年后)护肝胶囊组和红花清肝十三味丸组的癌变率明显低于非用药组。④动物实验表明:红花清肝十三味丸能使肝损伤大鼠转氨酶降低,具有显著的抗肝损伤作用。结论乙肝病毒携带者必须治疗,经治疗可降低血清中肿瘤标志物的浓度,使血清HBV-DNA浓度明显下降,预防肝细胞癌的发生。血清肿瘤标志物的浓度与血清乙肝病毒标志物的浓度呈正相关,与肝细胞癌的发生率呈负相关。
Objective To study the relationship of HBV tumor markers and hepatic carcinoma（HCC）. Methods We have studied 120 hepatitis B virus carrier,60 patients were treated with Hong Hua Qing Gan Shi San Wei Wan（HHQGSSWW） ,30 cases were treated with Hu Gan Jiao Nang （HGJN） and 30 cases without treatment. We have observed the change of tumor markers and five years follow - up. On the other hand, HBV - DNA was determind with FQ - PCR, We observed the effectiveness of preventing liver by HHQGSSWW on the liver injury model caused by CCl4 in Lab. Results （1） AFP,AFU,r- GT and CEA decreased clearly in the tratment group and no change in the untreated group ; （1）Five years follow - up proved HBV - DNA decreased clearly in the treatment group, and no change in the untreated- group, Five years follow- up proved canceration rate of the treatment groups is lower than that of the untreated group, （4）Animal experiment prove that this medicine can decrease ALT of the mice with liver injury, which proves its obvious function of anti - liver injury. Conclusion Hepatitis B virus carder must be treated. Through treatment tumor marker decreased apparently. We may reduce tumor markers to prevent the hepatitis B transfering to hepatoma.
出处
《医药论坛杂志》
2008年第4期1-2,共2页
Journal of Medical Forum
基金
河南省科技攻关项目(№0524410093)
